Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MDX-447 immune-modulating bispecific antibody against the EGF receptor: Phase II testing

(Milestone payment, B3)

Medarex Inc. (MEDX),

Read the full 69 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE